Tenosynovial giant cell tumors (TGCT): molecular biology, drug targets and non-surgical pharmacological approaches.
Geert SpierenburgLizz van der HeijdenKirsten van LangeveldeKároly SzuhaiJudith V M G BovéeMichiel Adreanus van de SandeAndré B P van KuilenburgPublished in: Expert opinion on therapeutic targets (2022)
The CSF1-CSF1R axis is the principal drug target; however, the effect of CSF1R inhibition on angiogenesis and the role of macrophages, which are essential in the postoperative course, needs further elucidation. Systemic therapies have a promising role in treating mainly diffuse-type, TGCT patients who are not expected to clinically improve from surgery. Future drug development should focus on targeting neoplastic TGCT cells.
Keyphrases
- giant cell
- induced apoptosis
- minimally invasive
- cell cycle arrest
- cerebrospinal fluid
- endothelial cells
- coronary artery bypass
- adverse drug
- drug induced
- low grade
- vascular endothelial growth factor
- cancer therapy
- cell death
- emergency department
- oxidative stress
- signaling pathway
- single molecule
- coronary artery disease
- surgical site infection
- electronic health record